Arca
Skip to content
Tools
Tools

Breast cancer

Drug research and approvals for breast cancer: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 2,449 studies of breast cancer are recruiting on ClinicalTrials.gov, Health Canada has authorized 267 drug trials for it since 2013, FDA has 7 approved and 6 open orphan designations naming it, and the EU has 50 authorised medicines for it.

  • Recruiting worldwide: 2,449
  • Trials authorized in Canada: 267
  • FDA orphan approvals: 7
  • EU medicines: 50

Recruiting now

Newest posted first, of 2,449 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition or a subtype of it, from ChEMBL's drug indications

Approved 24 of 48

Phase 3 12 of 150

Phase 2 12 of 399

Phase 1 or earlier 12 of 208

How its trials ended

11,325 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 2,474 whose ending is known, 34% met their primary endpoint, 8% missed it and 57% stopped early.

  • Completed, result not reported4,13937%
  • Ongoing3,20328%
  • Status unknown1,50913%
  • Met its primary endpoint8518%
  • Stopped: other or unclear6896%
  • Stopped: enrollment or feasibility3963%
  • Missed its primary endpoint2102%
  • Stopped: sponsor or business decision1511%
  • Stopped: lack of efficacy901%
  • Stopped: funding651%
  • Stopped: safety22<1%

Trials authorized in Canada

The 10 newest of 267; search them all in Canada trials
Oct 21, 2026A global, interventional, open-label trial of t-dxd-based therapy followed by palbociclib, endocrine therapy and dual HER2 blockade in first-line HER2+/HR+…Enhertu / Arimidex / Aromasin / Faslodex / Femara / Ibrance / Perjeta / Herzuma…Daiichi SankyoPending
Oct 15, 2026An open-label randomized phase 2 study to evaluate safety and efficacy of patritumab deruxtecan plus pembrolizumab administered either before or after…Patritumab deruxtecan (MK-1022) / Pembrolizumab (MK-3475)Merck & Co. (MSD)Pending
Aug 31, 2026A phase IIIb, single-arm, open-label, multicenter study evaluating the treatment adherence, tolerability, and patient-reported outcomes of giredestrant in…Giredestrant (GDC-9545, RO7197597) / Leuprolide / TriptorelinRocheOngoing
Jul 27, 2026Shorter anthracycline-free chemo immunotherapy adapted to pathological response in early triple negative breast cancer (SCARLET), a randomized phase III studyCarboplatin / Pembrolizumab (keytruda)BC Cancer, Part of The Provincial Health Services AuthorityPending
Jun 9, 2026An open label, multi-center alpelisib roll-over study to assess long-term safety in participants who have completed a novartis sponsored alpelisib (BYL719)…Alpelisib (BYL719) / FulvestrantNovartis PharmaceuticalsPending
Jun 5, 2026An open-label, multi-center, phase I/Ib study of IEV407 as a single agent and in combination with endocrine therapy in patients with advanced hormone receptor…IEV407 / Fulvestrant / LetrozoleNovartis PharmaceuticalsOngoing
May 6, 2026An open-label, multi-center, phase I/II study of ERW316 as a single agent or in combination with endocrine therapy in patients with HR+/HER2- breast cancer and…ERW316 / Fulvestrant / LetrozoleNovartis PharmaceuticalsClosed
Feb 13, 2026A phase 2, randomized, open-label dose optimization and phase 3, randomized, double-blind, placebo-controlled study of tersolisib (LY4064809) combined with a…Tersolisib (LY4064809, STX-478) / Abemaciclib / Ribociclib / Palbociclib /…Eli LillyPending
Feb 2, 2026A two-part, seamless, multicenter, randomized, open-label, adaptive phase II/III study of the blood-brain barrier penetrant RO7771950 versus tucatinib, both in…RO7771950 (ZN-A-1041) / Tucatinib / Trastuzumab (RO0452317) / CapecitabineRocheOngoing
Dec 17, 2025Rebooting sensitivity to checkpoint blockade therapy in triple-negative breast cancer with isunakinra (resett- i)IsunakinraUniversity Health NetworkOngoing

FDA orphan designations

Approved first, then open designations, newest first
Oct 7, 2026TukysaIn combination with trastuzumab and pertuzumab for the maintenance treatment of adult patients with unresectable locally advanced or…Seattle Genetics, Inc.Approved
Apr 17, 2020TucatinibTUKYSA is indicated in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or…Seattle Genetics, Inc.Approved
Sep 13, 2007EvistaReduction in risk of invasive breast cancer in postmenopausal women with osteoporosis and reduction in risk of invasive breast cancer in…Eli Lilly and CompanyApproved
Oct 21, 1999AromasinTreatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.Pharmacia & UpjohnApproved
Sep 15, 1999EllenceComponent of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer.Pharmacia & Upjohn CompanyApproved
May 29, 1997FarestonTreatment of metastatic breast cancer in postmenopausal women with estrogen positive or receptor unknown tumors.Orion CorporationApproved
May 26, 1995ZinecardCardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative dose of…Pharmacia & UpjohnApproved
Nov 20, 2024AzeliragonTreatment of breast cancer brain metastasesCantex PharmaceuticalsDesignated
Mar 21, 2024UtideloneTreatment of breast cancer brain metastasesBiostar Pharma, Inc.Designated
Nov 2, 2023BMEDA-chelated Rhenium-186 nanoliposomesTreatment of breast cancer with leptomeningeal metastases (LM)Plus Therapeutics, Inc.Designated
Feb 28, 2017(s)-perillyl alcohol temozolomide carbamateTreatment of intracranially located metastases from breast cancerNeOnc Technologies, Inc.Designated
Apr 15, 2015[α′N-(2′succinyl-paclitaxel)Thr]-Phe-Phe-Tyr-Gly-Gly-Ser-Arg…Treatment of breast cancer patients with brain metastasesAngiochem, Inc.Designated
Jul 28, 2004EfaproxiralAdjunct to whole brain radiation therapy for the treatment of brain metastases in patients with breast cancerAllos Therapeutics, Inc.Designated

Medicines authorised in the EU

Newest first; 15 of 50
Jul 20, 2026EtcamahCamizestrantAstraZeneca ABEMA ↗
Jun 19, 2026Palbociclib ViatrisPalbociclib · genericViatris LimitedEMA ↗
Jan 9, 2026InluriyoImlunestrantEli Lilly Nederland B.V.EMA ↗
Jun 30, 2025DazublysTrastuzumab · biosimilarCuraTeQ Biologics (Malta) LimitedEMA ↗
Apr 4, 2025DatrowayDatopotamab deruxtecanDaiichi Sankyo Europe GmbHEMA ↗
Sep 19, 2024TuznueTrastuzumabPrestige Biopharma BelgiumEMA ↗
Jul 26, 2024AvziviBevacizumab · biosimilarFGK Representative Service GmbHEMA ↗
Jul 24, 2024ApexelsinPaclitaxel · genericWhiteoak Pharmaceutical B.V.EMA ↗
Jun 27, 2024Eribulin BaxterEribulin · genericBaxter Holding B.V.EMA ↗
Jun 17, 2024TruqapCapivasertibAstraZeneca ABEMA ↗
Feb 9, 2024MevlyqEribulin · genericYES Pharmaceutical Development Services GmbHEMA ↗
Jan 5, 2024NaveruclifPaclitaxel · genericAccord Healthcare S.L.U.EMA ↗
Nov 15, 2023HerwendaTrastuzumab · biosimilarSandoz GmbHEMA ↗
Sep 15, 2023OrserduElacestrantStemline Therapeutics B.V.EMA ↗
May 31, 2022Zolsketil pegylated liposomalDoxorubicinAccord Healthcare S.L.U.EMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.